Ontology highlight
ABSTRACT:
SUBMITTER: Brummendorf TH
PROVIDER: S-EPMC7237399 | biostudies-literature | 2020 Jun
REPOSITORIES: biostudies-literature
Brümmendorf Tim H TH Gambacorti-Passerini Carlo C Bushmakin Andrew G AG Cappelleri Joseph C JC Viqueira Andrea A Reisman Arlene A Isfort Susanne S Mamolo Carla C
Annals of hematology 20200419 6
Patients with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) can be effectively treated with tyrosine kinase inhibitors (TKIs) and achieve a lifespan similar to the general population. The success of TKIs, however, requires long-term and sometimes lifelong treatment; thus, patient-assessed health-related quality of life (HRQoL) has become an increasingly important parameter for treatment selection. Bosutinib is a TKI approved for CP CML in newly diagnosed adults and in those res ...[more]